Research programme: parasitic disease therapeutics - Vyera Pharmaceuticals

Drug Profile

Research programme: parasitic disease therapeutics - Vyera Pharmaceuticals

Alternative Names: CDPK1 Inhibitor - Vyera Pharmaceuticals; DHFR Inhibitor - Vyera Pharmaceuticals; TRP 004; TRP 012; TRP 013

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Turing Pharmaceuticals
  • Developer Vyera Pharmaceuticals
  • Class Antiparasitics; Small molecules
  • Mechanism of Action ATCDPK1 protein inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Toxoplasmosis

Highest Development Phases

  • Preclinical Chagas disease; Malaria; Toxoplasmosis; Trypanosomiasis

Most Recent Events

  • 12 Apr 2018 Preclinical trials in Chagas' disease in USA (unspecified route) (Vyera pipeline, April 2018)
  • 12 Apr 2018 Preclinical trials in Malaria in USA (unspecified route) (Vyera pipeline, April 2018)
  • 12 Apr 2018 Preclinical trials in Trypanosomiasis in USA (unspecified route) (Vyera pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top